BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Medtronic
Citi
Healthtrust
Farmers Insurance
Fish and Richardson
Express Scripts
Mallinckrodt
Johnson and Johnson
Queensland Health

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,592,480

« Back to Dashboard

Which drugs does patent 8,592,480 protect, and when does it expire?

Patent 8,592,480 protects PHOSLYRA and is included in one NDA.

This patent has twenty-two patent family members in seventeen countries.
Summary for Patent: 8,592,480
Title:Liquid compositions of calcium acetate
Abstract: The invention relates to an aqueous liquid composition of calcium acetate, sweetener, and taste masking agent. Also provided is a method for binding phosphorus within the gastrointestinal tract of an individual by administering to the individual an aqueous solution of at least calcium acetate.
Inventor(s): Tarallo; Stephen C. (Brockton, MA)
Assignee: Lyne Laboratories, Inc. (Brockton, MA)
Application Number:13/162,938
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 8,592,480

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Fresenius Medcl PHOSLYRA calcium acetate SOLUTION;ORAL 022581-001 Apr 18, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe USE OF PHOSYLRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,592,480

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,591,938 Liquid compositions of calcium acetate ➤ Subscribe
9,089,528 Liquid compositions of calcium acetate ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,592,480

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Mexico 2009000722 ➤ Subscribe
South Korea 101553719 ➤ Subscribe
South Korea 20090040340 ➤ Subscribe
Japan 5335674 ➤ Subscribe
Japan 2009544615 ➤ Subscribe
Israel 196584 ➤ Subscribe
Hong Kong 1202815 ➤ Subscribe
Hong Kong 1129814 ➤ Subscribe
Spain 2382993 ➤ Subscribe
European Patent Office 2484352 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Accenture
US Department of Justice
Teva
Johnson and Johnson
McKinsey
Cantor Fitzgerald
McKesson
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot